The U.S. Food and Drug Administration has approved Taiho Oncology’s Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older or who are ineligible for intensive induction chemotherapy.
Continue Reading this article here
